Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib in Severe Cutaneous Scleroderma or Systemic Sclerosis
NCT00479934Phase 2Completed
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Dec 2007
- Primary completion
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in scleroderma and systemic sclerosis (SSc) comparing Imatinib with Placebo (2 arms). Primary endpoint: Modified Rodnan Skin Score at 6 months. Started Dec 2007; status: completed.
02
Drugs
03
Conditions
sclerodermasystemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT00479934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00479934.